Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Status:
Recruiting
Trial end date:
2022-02-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out about the potential benefits and safety of
brexpiprazole in children and adolescent subjects, aged 5 to 17, with irritability associated
with autism spectrum disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.